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Abstract
In recent years, there has been increased interest in the vascular component of airway remodelling in chronic
bronchial inflammation, such as asthma and COPD, and in its role in the progression of disease. In particular, the
bronchial mucosa in asthmatics is more vascularised, showing a higher number and dimension of vessels and vas-
cular area. Recently, insight has been obtained regarding the pivotal role of vascular endothelial growth factor
(VEGF) in promoting vascular remodelling and angiogenesis. Many studies, conducted on biopsies, induced sputum
or BAL, have shown the involvement of VEGF and its receptors in the vascular remodelling processes. Presumably,
the vascular component of airway remodelling is a complex multi-step phenomenon involving several mediators.
Among the common asthma and COPD medications, only inhaled corticosteroids have demonstrated a real ability
to reverse all aspects of vascular remodelling. The aim of this review was to analyze the morphological aspects of
the vascular component of airway remodelling and the possible mechanisms involved in asthma and COPD. We
also focused on the functional and therapeutic implications of the bronchial microvascular changes in asthma and
COPD.
Introduction
Bronchial vessels usually originate from the aorta or
intercostal arteries, entering the lung at the hilum,
branching at the mainstem bronchus to supply the
lower trachea, extrapulmonary airways, and supporting
structures. They cover the entire length of the bronchial
tree as far as the terminal bronchioles, where they ana-
stomose with the pulmonary vessels. The bronchial ves-
sels also anastomose with each other to form a double
capillary plexus. The external plexus, situated in the
adventitial space between the muscle layer and the sur-
rounding lung parenchyma, includes venules and
sinuses, and it constitutes a capacitance system. The
internal plexus, located in the subepithelial lamina pro-
pria, between the muscularis and the epithelium, is
essentially represented by capillaries. These networks of
vessels are connected by short venous radicles, which
pass through the muscle layer structure. The bronchial
submucosal and adventitial venules drain into the bron-
chial veins which drain into the azygos and hemiazygos
veins [1-3].
In normal airways, the bronchial microvasculature serves
important functions essential for maintaining homeostasis.
In particular, it provides oxygen and nutrients, regulates
temperature and humidification of inspired air, as well as
being the primary portal of the immune response to
inspired organisms and antigens [4]. The high density of
capillaries present is probably related to a high metabolic
rate in the airway epithelium, which is very active in secre-
tory processes. In fact, the oxygen consumption of airway
epithelium is comparable to that of the liver and the heart
[1]. In normal airways, the maintenance of vascular home-
ostasis is the result of a complicated interaction between
numerous pro- and anti-angiogenetic factors (Table 1).
Bronchial flow may be affected by alveolar pressure and
lung volume, with higher airway pressures decreasing
blood flow [5]. Moreover, the bronchial arteries have a-
and b-adrenergic receptors and it is known that adrenalin,
which has a-agonist effects, reduces total bronchial flow
as it does in other systemic vascular beds [6]. Lastly, vagus
stimulation may increase total bronchial flow [5].
During chronic inflammation, the vascular remodelling
processes are the consequence of the prevalence of a pro-
angiogenetic action, in which many growth factors and
inflammatory mediators are involved [7]. Accordingly,
the bronchial microvasculature can be modified by a
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variety of pulmonary and airway diseases. Congestion of
the bronchial vasculature may narrow the airway lumen
in inflammatory diseases, and the formation of new bron-
chial vessels, angiogenesis, is implicated in the pathology
of a variety of chronic inflammatory, infectious, and
ischemic pulmonary diseases [3,4,8]. Bronchiectasis and
chronic airway infections may be characterized by hyper-
vascularity and neo-vascularisation of the airway walls
[9]. Additionally, airway wall ischemia following lung
transplantation can induce new vessel formation [9]. The
remarkable ability of the bronchial microvasculature to
undergo remodelling has also implications for disease
pathogenesis.
Most of the literature regarding bronchial vascular
remodelling in chronic airway inflammation results from
studies in asthmatic patients [10-15], since the vascular
component of airway remodelling significantly contri-
butes to the alteration of the airway wall in asthma
(Figure 1). Interestingly, it has been recently shown that
bronchial vascular changes may also occur in COPD
[16-18]. Microvascular changes in asthma and COPD
may contribute to an increase in airway wall thickness
which may be associated with disease progression [9].
This review focuses on the morphological aspects of the
vascular component in airway wall remodelling in
asthma and COPD and its functional and therapeutic
implications.
Asthma
Early observations regarding bronchial vascular changes
in asthmatic airways date back to the sixties and con-
cern post-mortem analysis [19,20]. Dunnill and collea-
gues showed oedematous bronchial mucosa with dilated
and congested blood vessels in patients with fatal dis-
ease [19,20]. About thirty years later, some studies
demonstrated an increase in the percentage of blood
vessels in the airway walls; the concepts of vessel dilata-
tion, increased permeability and angiogenesis were
suggested [12,21].
Hyperaemia and hyperperfusion
An increased blood flow has been shown in the airways
of asthmatic patients, in comparison to healthy controls,
by measuring dimethyl ether in exhaled air [22]. Calcu-
lated as the volume of the conducting airways from the
trachea to the terminal bronchioles, mean airway blood
flow values were found to be 24-77% higher in asth-
matics than in healthy controls [22]. Increased blood
flow is likely due to the dilatation of arterioles and an
increased number of vessels.
Activation of pulmonary c-fibre receptors by irritants
and inflammatory mediators may induce vasodilatation
mainly via sympathetic motor nerves. Local axon
reflexes in response to irritants and inflammatory med-
iators may release vasodilator neuropeptides such as
substance P, neurokinins, and calcitonin gene-related
peptides [23]. Consequently, the airway inflammation in
asthma may evoke mucosal vasodilatation due to the
direct action of mediators on vascular smooth muscle,
neuropeptides released by axon reflexes from sensory
nerve receptors, and reflex vasodilatation due to stimu-
lation of sensory nerves [23]. Nitric oxide (NO) and
blood flow regulation abnormalities by the sympathetic
nervous system may be involved in hyperaemia and
hyperperfusion, even if the precise mechanisms are
unclear [24]. Notably, bronchial blood flow positively
correlates with both exhaled nitric oxide NO and breath
Table 1 Inducers and inhibitors of angiogenesis
Angiogenetic inducers Angiogenetic inhibitors
Inflammatory mediators Soluble mediators
IL-3, IL-4, Il-5, IL-8, IL-9, IL-13 IFN-a, IFN-b, IFN-g
TNFa Ang-2
Prostaglandin E1, E2 TIMP-1, TIMP-2
Growth Factors IL-4, IL-12, IL-18
VEGF Troponin
FGF-1, FGF-2 VEGI
PDGF TSP-1, TSP-2
PIGF PF-4
IGF Protein fragments
TGFa, TGFb Angiostatin
EGF Endostatin
HGF aaAT
HIF Prolactin
PD-ECGF Vasostatin
Enzymes Tumor suppressor genes
COX-2 P53
Angiogenin NF1, NF2
MMPs RB1
Hormones DCC
Estrogens WT1
Gonadotropins VHL
TSH
Proliferin
Oligosaccharides
Hyaluronan
Gangliosides
Cell adhesion molecules
VCAM-1
E-selectin
avb3
Hematopoietic factors
GM-CSF
Erythropoietin
Others
Nitric oxide
Ang-1
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temperature in asthmatic subjects [25]. Exhaled breath
temperature and bronchial blood flow may reflect rubor
and calor in the airways, and therefore may be markers
of tissue inflammation and remodelling [25].
Microvascular permeability
Increased microvascular permeability and oedema are
common features during vascular remodelling in bron-
chial asthma [26]. Electronic microscopy studies have
shown that in the lower airways of most species, includ-
ing healthy humans, only the capillaries underlying neu-
roepithelial bodies are fenestrated, the rest having a
continuous epithelium [1]. By contrast, in some animal
species the lower airway capillaries are fenestrated [27].
Interestingly, this feature is also observed in asthmatic
patients [27]. Using animal models, McDonald et al [27]
suggested a role for intercellular gaps between endothe-
lial cells of postcapillary venules in microvascular per-
meability. Some reports confirmed the relevant presence
of this phenomenon in airways of asthmatic patents
[28-33]. In these studies, microvascular permeability was
evaluated by the airway vascular permeability index as
measured by the albumin in induced sputum/albumin in
serum [28-31], or as fibronectin concentrations [32] or
alpha 2-macroglobulin levels [33] in BAL fluid.
Plasma extravasations can compromise epithelial
integrity and contribute to formation luminal mucus
plugs [34]. Plasma leakage can also lead to mucosal
oedema and bronchial wall thickening, thereby reducing
the airway lumen, which in turn causes airflow limita-
tion and may contribute to airway hyperresponsiveness
[35,36]. Furthermore, during the chronic inflammation
process, new capillaries are immature and unstable and
can contribute to increased permeability [36]. The
increased microvascular permeability is due to the
release of inflammatory mediators, growth factors, neu-
ropeptides, cytokines, eosinophil granule proteins, and
proteases (Table 2).
Vascular endothelial growth factor (VEGF) is a potent
angiogenic factor, proven to be increased in asthma and
correlated to the vascular permeability of airways
[28-30], as well as shown to determine gaps in the
Figure 1 Schematic picture of normal (left) and asthmatic airway (right), indicating the remodelling of compartments, with particular
regards to microvascular alterations.
Table 2 Factors involved in the bronchial vasculature
remodelling in asthma and COPD
Angiogenesis Vasodilatation Permeability
VEGF VEGF VEGF
FGF Histamine Histamine
TGFb Heparine Adenosin
HGF Tryptase Bradychinin
HIF NO Ang-1, Ang-2
Ang-1 TGFa, TGFb SP
Histamine FGF CGRP
PGD2 EGF LTB4, LTC4, LTD4
PGI2 IL-4 PAF
LTC2 TNFa ET-1
PAF LTC4 TNFa
SP PGD2 ECP
VIP
IL-8, IL-13
TNFa
NKA
Angiogenin
MMPs
IGF-1
Chymase
VCAM-1
E-selectin
avb3
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endothelium [37]. Angiopoietin-1 is known to stabilize
nascent vessels, making them leak resistant, while
Angiopoietin-2 reduces vascular integrity. Angiopoietin-
2, but not angiopoietin-1, is positively correlated to the
airway vascular permeability index [31]. Greiff et al [38]
found that histamine was able to induce plasma extrava-
sation with consequent bronchial exudation in healthy
subjects. Similarly, bradykinin can determine plasma
exudation in human peripheral airways. Berman et al
[39] performed BAL in airways of normal and asthmatic
subjects before and after challenges with bradykinin,
aerosolized through a bronchoscope. They observed an
increase in fibrinogen levels in the BAL fluid from both
groups, thereby suggesting bradykinin-induced micro-
vascular leakage [39].
Angiogenesis
Unlike the pulmonary circulation, the bronchial vessels
are known to have a considerable ability to proliferate
during several pathological conditions. Leonardo da
Vinci is generally regarded as the first person to observe,
around a cavitatory lesion in human lung, the presence
of vascular phenomena, that could be interpreted as
angiogenetic processes [40]. In the last two decades,
many reports have documented angiogenesis of bron-
chial vessels in response to a wide variety of stimuli,
including chronic airway inflammation. Angiogenesis
can be defined as the formation of new vessels by
sprouting from pre-existing vessels [41]. With a broad
meaning, lengthening and enlargement of existing ves-
sels are also considered to be angiogenesis, whereby the
vessels take a more tortuous course.
To explore and quantify the bronchial microvascula-
ture, different methodological approaches are possible.
Biopsy specimens from post-mortem resections provide
considerable amounts of tissue with good clinical char-
acterisation [11,21]. Similarly, lung resection studies
allow for harvesting of pulmonary tissue in reasonable
quantities, even if the tying procedure at the resection
margin could influence the bronchial vascular conges-
tion [21]. Fiberoptic bronchoscopy offers the possibility
of obtaining repeated samples from the same patients,
with varying disease severity, and evaluating pharmaco-
logical effects [42]. Finally, high magnification video
bronchoscopy, a more recent and less invasive techni-
que, is also useful to study the bronchial microvascular-
ity in asthma and COPD [43,44].
Immunohistochemical analysis represents the gold
standard approach to quantify bronchial microvascu-
larity. The quantification of bronchial vessels generally
includes the number of vessels per square millimetre
of area analyzed, the vascular area occupied by the ves-
sels, expressed as percentage of the total area evalu-
ated, and the mean vessel size, estimated by dividing
the total vascular area by the total number of vessels
[12,17,42,45,46].
Two studies used the monoclonal antibody against
factor VIII and analyzed the entire submucosa, finding
both an increase vascular areas and vessel dimensions in
asthmatic patients in comparison to healthy controls
[11,21]. Furthermore, to obtain a better identification of
the bronchial microvascularity, some groups of authors
used the monoclonal antibody against collagen type IV
[12,42,45-47], and performed the quantification in the
supepithelial lamina propria [12,42,45,47] or in the
entire submucosa [46]. Except for the Orsida study [45],
which showed that asthmatics had only an increase in
vascular area when compared to healthy controls, the
other studies found an increase both in vessel number
and in vascular area [12,42,46]. Salvato stained his
sections with a combination of haematoxylin-eosin,
Masson trichrome, PAS, alcian blue-PAS and orcein,
and evaluated microvessels in the supepithelial lamina
propria, showing an increase in vessel number and
vascular area [13]. Moreover, some studies used the
monoclonal antibody anti-CD31 [17,47,48], apparently
more vessel-specific, but further investigation is required
to obtain a better technique to measure the various
aspects of angiogenesis [49].
In asthmatic patients, even with mild to moderate
disease, a significant increase in the number of vessels
and/or percent vascular area, as well as an increased
average capillary dimension, can be observed in compar-
ison to healthy controls [12,13,17,42,45-47]. Further-
more, a relationship between increased bronchial
microvascularity and the severity of asthmatic disease
was found [13,17,50]. Finally, the vascular component of
airway remodelling in asthma does not appear related to
the duration of the disease, given that it can be detect-
able even in asthmatic children [48].
Angiogenesis should be considered to be a complex
multiphase process, potentially involving a great number
of growth factors, cytokines, chemokines, enzymes and
other factors (Table 2 and Figure 2). The specific role of
each molecule has not been clearly defined, even if
VEGF is considered to be the most important angio-
genic factor in asthma [51]. Many biopsy studies
[47,52-54], as well as reports conducted on induced
sputum [28-31], have observed higher VEGF levels in
asthmatic airways when compared to those of healthy
controls. In particular, immunohistochemical studies
demonstrated close relationships between VEGF expres-
sion and vascularity [47,52-54]. Hoshino et al [53] found
an increased staining of mRNA for VEGF receptors (R1
and R2) on bronchial endothelium in asthmatic patients
versus normal subjects. Feltis et al. [47] showed a rela-
tionship between VEGF and VEGF-R2 expression in
asthma and between VEGF and VEGF-R1 in controls.
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It is of note that VEGF-R2 is the major mediator of
the mitogenic, angiogenic and permeability-enhancing
effects of VEGF, while VEGF-R1 has been suggested to
act as a modulating decoy to VEGF-R2, thereby inhibit-
ing VEGF-VEGF-R2 binding [55]. Therefore, it is plausi-
ble that VEGF-R2 is actively engaged in enhanced VEGF
activity in asthma, possibly contributing to an increase
in VEGF-induced microvascular remodelling [47]. Inter-
estingly, Feltis et al [47] observed cystic structures
within the vessel walls, that they termed angiogenic
sprouts. The number of sprouts was markedly increased
in asthmatics, and the increase in sprouts per vessel was
positively related to the VEGF expression [47].
The angiopoietin family can play a role in vascular
remodelling of asthmatic airways. Angiopoietin-1 (Ang-
1) is known to stabilize new vessels, while angiopoietin-
2 (Ang-2), in the presence of VEGF, acts as an Ang-1
antagonist, making vessels unstable and promoting ves-
sel sprouting [47]. In contrast, endostatin is known to
be a strong endogenous inhibitor of angiogenesis [56].
Interestingly, an imbalance between VEGF and endosta-
tin levels was found in induced sputum from asthmatic
patients [28]. In biopsies from asthmatic patients,
Hoshino et al [52], showed higher expression of basic
fibroblast growth factor (bFGF) and angiogenin, with
significant correlations between the vascular area and
the number of angiogenic factor-positive cells within the
airways.
Metalloproteinases (MMPs) can also play a role in the
angiogenic processes. MMPs are a large family of zinc-
and calcium-dependent peptidases, which are able to
degrade most components of tissue extracellular matrix.
This function represents an essential requirement to
permit cell migration in tissue, lengthening of existing
vessels, and sprouting and formation of new vessels. Lee
et al. [57] found that levels of VEGF and MMP-9 were
significantly higher in the sputum of patients with
asthma than in healthy control subjects, as well as a sig-
nificant correlation between the levels of VEGF and
MMP-9 was present. Moreover, administration of VEGF
receptor inhibitors reduced the pathophysiological signs
of asthma and decreased the expression of MMP-9 [57].
Many inflammatory cells are probably involved as
angiogenic growth factor sources in the asthmatic
Figure 2 Schematic picture of the angiogenic processes, indicating the activation and proliferation of endothelial cells.
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airways. Mast cells are known to be one of the most
important sources of proangiogenic factors [58]. Mast
cells can secrete several mediators involved in angiogen-
esis, such as VEGF, bFGF, TGFb, MMPs, histamine,
lipid-derived mediators, chemokines (IL-8 in particular),
cytokines, and proteases (Table 3). Co-localization stu-
dies revealed that both tryptase-positive mast cells and
chymase-positive mast cells can play a role in the vascu-
lar component of airway remodelling in asthma, through
induction of VEGF [54,59]. Other studies showed that in
asthmatic patients, eosinophils, macrophages and CD34-
positive cells can be involved as angiogenic growth fac-
tor sources [52,53].
COPD
The microvascular changes in the bronchial mucosa of
COPD patients have recently aroused researchers’ inter-
est. Bosken et al [60] reported that the airways of patients
with COPD were thicker than those of controls. Perform-
ing a morphometric analysis, they observed that muscle,
epithelium, and connective tissue were all increased in
the obstructed patients, and suggested that airway wall
thickening contributes to airway narrowing. Kuwano et
al. [21] conducted the first study on bronchial vascularity
including COPD patients. They observed no difference in
vascular area and number of vessels between COPD and
controls, so the airway wall thickening in COPD patients
was ascribed to an increase in airway smooth muscle.
Notably, the lack of difference in vascularity between
COPD and controls in the Kuwano study was probably
due to the use of Factor VIII, which is not the gold
standard to outline vessels [49].
More recently, Tanaka et al [43] assessed the airway
vascularity in patients with asthma and COPD using a
high-magnification bronchovideoscope and did not find
any difference between COPD patients and controls
[43]. A drawback of this technique is the detection limit
of the bronchovideoscope and the incapacity to detect
small vessels, with a size approximately less than 300 μ2.
Using immunohistochemistry and staining vessels with
anti-CD31 monoclonal antibodies, Hashimoto et al. [17]
showed that the number of vessels in the medium and
small airways in asthmatic patients was increased, com-
pared to those in COPD patients and controls. Further-
more, the vascular area was significantly increased in
the medium airways in asthmatics and in the small
airways in COPD patients, as compared to controls.
Calabrese et al. [18] performed an immunohistochemical
study on bronchial biopsies taken from the central air-
ways of smokers with and without obstruction, using
monoclonal antibodies against collagen type IV to out-
line vessels. They observed an increase both in vascular
area and number of vessels in current smokers with
COPD and in symptomatic smokers with normal lung
function, when compared to healthy non-smokers [18].
In the central airways of clinically stable patients with
COPD who were not current smokers, we could demon-
strate a higher vascular area, but not an increase in the
number of vessels, when compared to control subjects
[61]. In spite of the differences in methods and patient
selection criteria, all these studies [17,18,61] consistently
found an increased vascular area in the airways of
patients with COPD (Figure 3).
Interestingly, in a heterogeneous group of COPD
patients with different comorbidities, such as lung can-
cer, bronchiectasis, lung transplantation, and chronic
lung abscess, Polosukhin et al [62] found that reticular
basement membrane thickness was increased and the
subepithelial microvascular bed was reduced in associa-
tion with progression from normal epithelium to squa-
mous metaplasia. Recently, a group actively researching
this area provided preliminary data which showed the
presence of splitting and fragmentation of the reticular
basement membrane associated with altered distribution
of vascularity between the reticular basement membrane
and the lamina propria in COPD patients and smokers
as compared to controls [63,64].
Like in asthma, VEGF is implicated in the mechanisms
of bronchial vascular remodelling in COPD. Kanazawa
et al. [65] showed increased VEGF levels in induced
sputum from patients with chronic bronchitis and
asthma, and decreased levels from patients with emphy-
sema, as compared to controls. Moreover, VEGF levels
were negatively related to lung function in chronic
bronchitis, but positively in emphysema, suggesting dif-
ferent actions in these two COPD subtypes [65]. By ana-
lysing the bronchial expression of VEGF and its
receptors, Kranenburg et al. [66] showed that COPD
was associated with increased expression of VEGF in
the bronchial, bronchiolar and alveolar epithelium, in
macrophages as well as in vascular and airway smooth
muscle cells. More recently, Calabrese et al. [18] found
an association between increased bronchial vascularity
and both a higher cellular expression of VEGF and a
vascular expression of a5b3 integrin. Interestingly, a5b3
Table 3 Major mast cells mediators, many of which have
angiogenic activity
Mediators Histamine, Tryptase, Chymase, Heparine,
Carboxypeptidase A, MMP-2, MMP-9
Cytokines IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10,
IL-13, TNFa
Chemokines RANTES, Eotaxin, MCP-1, MCP-3,
MCP-4, IL-8
Growth Factors VEGF, bFGF, TGFb, GM-CSF, PDGF,
PAF
Lipid-derived compounds PGD2, LTB4, LTC4, LTD4, LTE4
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integrin is an adhesion molecule that is upregulated in
new vessel proliferation in response to angiogenic sti-
muli, while it is not expressed or only at low levels in
resting endothelium [67].
An increased expression of FGF-1 and FGF-2 was
found by Kranenburg et al. [68] in the bronchial epithe-
lium of COPD patients. Additionally, FGF receptor-1
(FGFR-1) was detected in bronchial epithelial and airway
smooth muscle cells and in the endothelium of bron-
chial vessels. Interestingly, a positive correlation between
FGF-1 expression and pack-years was found, indicating
that the degree of pulmonary FGF-1 expression may be
related to the amount of airway exposure to smoke [68].
The extracellular matrix proteins may play a role in the
remodelling of airways and blood vessels in COPD. In
COPD patients, as compared to non-COPD patients an
increased staining for fibronectin in the neointima, for
collagen type IV and laminin in the medial layer, and
for collagen type III in the adventitial layer of bronchial
vessel walls was observed [69]. Polosukhin et al. [62]
showed that in patients with COPD the percentage of
HIF-1a positive epithelial cells significantly increased
with reduction in blood vessel number, thickness of the
reticular basement membrane and increased epithelial
height. Other growth factors, involved in vascular
changes during chronic inflammatory or neoplastic pro-
cesses, such as EGF, IGF, PDGF and HGF [70] may also
be involved in the vascular component of the bronchial
remodelling in COPD, however experimental data are
lacking in this area. Similarly, MMPs could also play a
role in angiogenesis in COPD, as well as in asthma,
however, this area of research has yet to be investigated.
Likely analogous to COPD, but much more rapid in
onset, vascular changes may occur after lung transplan-
tation. As reported by Walters and co-workers [9], over
recent years attention has been given to airway inflam-
mation and remodelling post lung transplantation. The
pathologic airway changes observed show the character-
istics of bronchiolitis obliterans syndrome. Angiogenic
remodelling seems to occur early and it is not related to
airflow limitation. Vessel number and vascular area are
higher than in controls, and they are probably related to
IL-8 and other C-X-C chemokines rather than VEGF
levels [9].
Significance of the vascular component of airway
remodelling
Bronchial microvasculature changes may result in airway
wall thickening and in the reduction of the lumenal
area. Several studies on bronchial vascular remodelling
in asthma and COPD showed significant correlations
between morphological or biological data (number of
vessels, vascular area, expression of angiogenic factors)
and lung function parameters, such as FEV1
[17,28,30,45,46,52,53,66,68], FEV1/FVC [29,68] and air-
way hyperresponsiveness [29,36,45,46]. The functional
effects of vascular remodelling may be amplified by
Figure 3 Microphotographs from a normal subject (upper
panel), asthmatic patient (middle panel) and COPD patient
(lower panel) showing bronchial mucosa stained with antibody
directed against Collagen IV to outline vessels. Original
magnification × 400.
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pre-existing airway wall architecture modifications, such
as bronchial mucosal thickening, cellular infiltration,
collagen deposition and bronchial smooth muscle
changes [71,72].
In functional terms, the airway wall can be considered
as the sum of three distinct layers and the thickening of
each can have separate effects [72]. The thickening of
the inner airway wall layer (epithelium, lamina reticu-
laris, and loose connective tissue between the lamina
reticularis and the airway smooth muscle (ASM) layer)
can amplify the effect of ASM shortening; the thicken-
ing of the outer (or adventitial) layer could decrease the
static and dynamic loads on the ASM; and an increase
in the ASM layer thickness can increase the strength of
the muscle. In addition, the remodelling of the connec-
tive tissue in the smooth muscle compartment could
increase or decrease the amount of radial constraint
provided to the ASM. Finally, thickening and fibrous
connective tissue deposition in all layers could decrease
airway distensibility and allow ASM adaptation in
shorter lengths [72].
Hypertrophy and hyperplasia of mucous glandular
structures and loss of alveolar attachments are consid-
ered to be the main structural changes of airway remo-
delling in COPD and they may play a crucial role in the
functional effects of airway remodelling (Table 4) [73].
However, in COPD patients the exact explanation for
the link between structural airway changes, with particu-
lar reference to the vascular component, and the func-
tional and clinical consequences are not yet clearly
defined and further studies are needed.
Bronchial vascular remodelling and
pharmacological modulation
The bulk of the literature regarding the pharmacological
effects on the vascular component of airway remodelling
has been obtained from studies in asthmatic patients.
The efficacy of anti-asthma drugs on vascular remodel-
ling is schematically presented in Table 5. Inhaled corti-
costeroids are the only treatment able to positively
affect all three main aspects of the vascular component
of airway remodelling: vasodilatation, increased micro-
vascular permeability and angiogenesis. Several studies
on asthmatic airways indicate that high doses of inhaled
corticosteroids (approximately a daily dose of BDP and
FP ≥ 800 μg) may reverse the increased vascularity
[28,29,42,45,46,54], while there is no consensus on the
duration of treatment. Notably, this important effect
seems to be especially mediated by a reduced expression
of VEGF by inflammatory cells [28-30,54,74].
Less experimental evidence is available on the actions
of long-acting b2 agonists (LABAs) and leukotriene
receptor antagonists (LTRAs) on decreasing the vascular
component of airway remodelling. Three months of
treatment with salmeterol, in a placebo-controlled study,
showed a significant decrease in the vascularity in the
lamina propria of asthmatics [75]. This may have been
caused by reduced levels of the angiogenic cytokine IL-8
following salmeterol treatment [76]. Moreover, among
anti-leukotrienes, montelukast has proven to have an
acute effect on decreasing airway mucosal blood flow,
similar to inhaled steroids [77].
There is a dearth of published data regarding the
effect of current therapies for COPD on bronchial
microvascularity. Recently, in a cross-sectional study on
COPD patients, we found that, as compared to
untreated patients, treated patients with long-term high
doses of beclomethasone showed lower values of vascu-
lar area and lower expression of VEGF, bFGF, and
TGFb [61]. Further prospective studies are needed to
confirm this finding and to assess the possible role of
Table 4 Main structural changes in airway remodelling and respective functional effects in asthma and COPD
Structural changes Functional effects Asthma COPD
Vascular remodelling with inner airway wall
thickening
Decreased baseline airway calibre and amplification of airway smooth muscle
shortening
+++ +
Hypertrophy and hyperplasia of airway smooth
muscle
Increased smooth muscle strength and airway hyperresponsiveness +++ +
Connective tissue deposition Increased airway smooth muscle radial constraint +++ +
Thickening and fibrosis of all layers Decreased airway distensibility and reduced effectiveness of bronchodilators ++ +
Hypertrophy and hyperplasia of mucus gland Decreased lumen calibre and amplification of airway smooth muscle
shortening
+ +++
Loss of alveolar attachments Predisposition to expiratory closure and collapse - +++
Table 5 The efficacy of anti-asthma drugs on aspects of
the vascular components of airway remodelling
Corticosteroids LABA LTRAs
Microvascular leakage +++ ++ +
Vasodilatation +++ - +
Angiogenesis +++ + -
+++ = highly effective; ++ = effective; + = moderately effective; - = ineffective
N.B.: due to the lack of data regarding theophylline, we excluded it from the
table
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bronchodilators on the bronchial microvascularity in
COPD.
Finally, several inhibitors of angiogenesis have been
studied in vitro and consequently progressed to clinical
studies. Some of them have shown promising results in
lung cancer, but these molecules have not yet been
investigated in chronic airway disease [78]. In the future,
these compounds, especially the therapeutic agents that
antagonize the effect of VEGF and/or prevent its pro-
duction could represent a novel approach for positively
acting on bronchial microvascular changes in asthma
and COPD (Table 6).
Conclusions
In the last two decades there has been an increasing
interest in the microvascular changes of bronchial air-
way mucosa during chronic inflammation, such as
asthma and COPD. Up to now, the focus of researchers
has been on asthma, while little work has been done in
COPD. Moreover, the effects of smoking on bronchial
microvascularity need better differentiation from the
specific changes due to airflow obstruction.
Although evidence suggests that there are vessel
changes in the bronchial wall in both asthma and
COPD, there are distinct differences in detail between
these situations. Angiogenesis seems to be a typical find-
ing in asthma, while, in COPD, little evidence supports
the view that vasodilatation is prevalent.
Microvascular changes in the bronchial airway mucosa
are probably the consequence of the activities of many
angiogenic factors, but VEGF seems to be crucially
involved both in asthma and COPD, and different types
of cells can play a role as the source of VEGF.
The clinical and functional relevance of the vascular
remodelling remains to be determined both in asthma
and COPD; even if some reports suggest that the vascu-
lar component of airway remodelling may contribute to
worsening of airway function.
There are few data regarding the effects of current
therapies on bronchial vascular remodelling. Some longi-
tudinal studies were conducted in asthma, with biopsy
quantification of vascular changes. These studies showed
that inhaled corticosteroids could effectively act on
vascular remodelling in asthmatic airways, partially rever-
sing microvascular changes. Evidence from a cross-
sectional study suggests also that long-term treatment
with inhaled corticosteroids is associated with a reduc-
tion in airway microvascularity in COPD.
Better knowledge about angiogenic processes and their
consequences in the airway wall both in asthma and
especially COPD are urgently needed, as well as new
therapeutic strategies for these conditions.
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Table 6 Drugs potentially active on airway vascular remodelling
Name Type of compound Mode of Action
Drugs active on
VEGF
Bevacizumab
Humanized IgG1 monoclonal antibody against VEGF Neutralization of VEGF
VEGF Trap Engineered soluble receptor Prevention of ligand binding
Sorafenib, Sunitinib Multitargeted receptor tyrosine kinase inhibitors Inhibition of signal transduction and
transcription
Neovastat Multifunctional agent obtained from dogfish cartilage Interference with VEGFR2
Induction of EC apoptosis
Inhibition of MMP activities
Drugs active on FGF
SU6668
Competitive inhibitor of FGFR1, Flk-1/KDR, PDGFRb via receptor tyrosine
kinase
Inhibition of signal transduction and
transcription
Drugs active on TGFb
SR2F
Antagonist of the soluble receptor:Fc fusion protein class Neutralization of TGFb
Drugs active on
MMPs
AZ11557272
MMP-9/MMP-12 inhibitor Inhibition of collagen and elastin destruction
EC = endothelial cell, FGF = fibroblast growth factor, MMP = metalloproteinase, PDGF = platelet-derived growth factor, TGF = transforming growth factor, VEGF =
vascular endothelial growth factor
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